


PU3611USW

Complete Listing of Pending Claims

1. (Original) Enantiomerically enriched 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid, or a pharmaceutically acceptable salt or solvate thereof.
2. (Original) The enantiomerically enriched compound of Claim 1 wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 90% of said compound.
3. (Previously presented) The enantiomerically enriched compound of Claim 2, wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 99% of said compound.
4. (Previously presented) A pharmaceutical composition comprising the enantiomerically enriched compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers and or excipients.
5. (Currently amended) A method for treating a CCK-A mediated disease or condition comprising administration to a mammal ~~of an effective~~ amount of compound as claimed in claim 1.
6. (Currently amended) A method for treating a CCK-A mediated disease or condition comprising administration to a mammal ~~of the a~~ pharmaceutical composition as claimed in Claim 4.
7. (Previously presented) The method as claimed in claim 5, wherein said disease or condition is obesity, gallbladder stasis, or diabetes.

PU3611USW




8. (Previously presented) The method as claimed in claim 5, wherein said disease or condition is obesity.
9. (Previously cancelled). ~~The use of a compound as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of a CCK A mediated disease or condition.~~
10. (Currently amended) A process for the preparation of a compound ~~as claimed in~~ of claim 1 which comprises:
- (a) resolution of racemic 3-[3-[1-(isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido]-benzoic acid by chiral hplc;
- (b) reaction of the appropriate enantiomer of the amine of formula (II)



(II)


with the isocyanate of formula (III), imidazolidine of formula (IV) or optionally substituted phenyl carbamate of formula (V)

PU3611USW



followed by removal of the carboxy protecting group R.


11. (Currently amended) A process ~~as claimed in~~ according to claim 10 wherein ~~the required compound of claim 1 is prepared~~ said preparation is via the racemic amine (II) which has been prepared by




concomitant reduction and hydrogenolysis of the oxime (VI), wherein R₂ is an optionally substituted benzyl group.

12. (Currently amended) A process ~~as claimed in~~ according to claim 11 wherein the oxime (VI) is prepared from the ortho phenylene diamine (VII) and an activated derivative of the diacid (VIII),

PU3611USW



(VII)



(VIII)

wherein, R₂ is an optionally substituted benzyl group.

- ~~13. (Cancelled) A medicament for the treatment of a CCK-A mediated disease or condition comprising the compound of Claim 1.~~